York Capital Management Global Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

York Capital Management Global Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-748,371	Closed	-$50.4M	–	40
2019 Q3	$50.4M	Sell	748,371 -368,356	-33%	-$28.4M	2.34%	12
2019 Q2	$95.6M	Buy	+1,116,727	New	+$95.5M	3.88%	9
2017 Q3	–	Sell	-601,040	Closed	-$54.6M	–	71
2017 Q2	$54.6M	Sell	601,040 -4,639	-0.8%	-$422K	1.14%	27
2017 Q1	$53.2M	Buy	605,679 +152,898	+34%	+$13.6M	1.28%	21
2016 Q4	$37.5M	Buy	+452,781	New	+$38.9M	1.01%	24

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

York Capital Management Global Advisors's BMRN Position: Q4 2019 in Review

York Capital Management Global Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 748,371 shares — an estimated $50.4M sold.

York Capital Management Global Advisors first reported a position in BMRN in Q4 2016 and held it in 5 quarters. The position peaked at $95.6M in Q2 2019. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

York Capital Management Global Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
York Capital Management Global Advisors sold 748,371 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $50.4M.
York Capital Management Global Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 5 quarters.
York Capital Management Global Advisors's BioMarin Pharmaceuticals position peaked at $95.6M in Q2 2019.
467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on York Capital Management Global Advisors's 13F filing for Q4 2019, filed 18 Feb 2020.